Platelet Features and Derivatives in Osteoporosis: A Rational and Systematic Review on the Best Evidence.
Francesca Salamanna, Melania Maglio, Maria Sartori...
https://pubmed.ncbi.nlm.nih.gov/32143494/Actively Recruiting
Led by Istituto Ortopedico Rizzoli · Updated on 2026-05-28
120
Participants Needed
2
Research Sites
8 weeks
Total Duration
Osteoporosis is a common chronic bone disease marked by decreased bone mineral density, which raises the risk of fractures. Current guidelines use Dual-X-ray Absorptiometry DXA as the standard for measuring bone density, but it alone does not accurately predict osteoporosis stages or fracture risk. This research aims to improve osteoporosis diagnosis by studying the vitality of peripheral blood mononuclear cells PBMCs and how they relate to bone health and disease severity, considering gender differences as well. The study evaluates a diagnostic test analyzing PBMCs from about 2-5 mL of blood from healthy individuals, osteopenic patients, and osteoporotic patients with or without fractures. Participants are grouped based on bone density and fracture status, with DXA results used for classification. The study builds on a patented method to better understand PBMC behavior and its link to bone metabolism changes, including correlations with DXA scores and blood markers related to osteoporosis. Participants will undergo blood sampling to assess PBMC vitality and biological activity. Researchers will also collect DXA data and blood parameters such as platelet counts and immune markers. The main outcome is the tests sensitivity and specificity in identifying osteoporosis risk by January 2026. The study involves periodic follow-ups and outpatient visits, with overall participant monitoring continuing until February 2027 to validate this new diagnostic approach.
CONDITIONS
Peripheral Mononuclear Cells to Screen, Monitor and Stratify the Population at Risk of Osteoporosis and Fractures
A
Alberto Corrado Di Martino
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Istituto Ortopedico Rizzoli
Lead Sponsor
Azienda Ospedaliero Universitaria Policlinico G.Rodolico - San Marco
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Single timepoint
Participants provide blood samples to assess the vitality and biological activity of peripheral blood mononuclear cells (PBMCs) and undergo related diagnostic tests to evaluate bone metabolism alterations.
1 visit (in-person)
Duration - Up to 3 years
Participants are monitored over time to correlate blood test results with bone density and fracture risk, with assessments based on follow-up outpatient visits and periodic screening as per clinical practice.
Periodic outpatient visits depending on clinical follow-up
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
4
Have more questions? Get in touch with our team for quick support
Francesca Salamanna, Melania Maglio, Maria Sartori...
https://pubmed.ncbi.nlm.nih.gov/32143494/F Salamanna, R Giardino, M Fini
https://pubmed.ncbi.nlm.nih.gov/29150298/Francesca Salamanna, Melania Maglio, Veronica Borsari...
https://pubmed.ncbi.nlm.nih.gov/26284737/Francesca Salamanna, Silvia Brogini, Alberto Di Martino...
https://pubmed.ncbi.nlm.nih.gov/41113706/Francesca Salamanna, Melania Maglio, Gianluca Giavaresi...
https://pubmed.ncbi.nlm.nih.gov/26250906/Istituto Ortopedico Rizzoli
Lead Sponsor
Azienda Ospedaliero Universitaria Policlinico G.Rodolico - San Marco
Collaborating Sponsor